SCHEMBL148199

SCHEMBL148199

CC(C)CC(=O)Nc1ccc2c(c1)[nH]c1ccccc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.61
RAB9A P51151 4/20 0.61
NPC1 O15118 3/20 0.61
CYP1A2 P05177 1/20 0.61
CYP2C9 P11712 1/20 0.61
CYP2C19 P33261 1/20 0.61
GAA P10253 1/20 0.58
MAOA P21397 1/20 0.58
KDM4E B2RXH2 6/20 0.55
KMT2A Q03164 2/20 0.55
MTNR1A P48039 1/20 0.55
MTNR1B P49286 1/20 0.55
HPGD P15428 2/20 0.54
LMNA P02545 1/20 0.54
P2RY12 Q9H244 2/20 0.53
MAPK1 P28482 1/20 0.53
TP53 P04637 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
PTPN1 P18031 1/20 0.51
ROCK2 O75116 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL150770 0.82 MAOA (0.62) SMN1; SMN2RAB9ANPC1GAAMAOA
SCHEMBL148317 0.81 P2RY12 (0.63) MAOAKDM4EKMT2AMTNR1AMTNR1B
SCHEMBL22616930 0.80 MAOA (0.86) MAOAKDM4EKMT2AMTNR1AMTNR1B
SCHEMBL147307 0.80 ROCK2 (0.73) RAB9ANPC1GAAMAOAKDM4E
SCHEMBL147687 0.80 MAOA (0.59) SMN1; SMN2MAOAKDM4EKMT2AMTNR1A
SCHEMBL147474 0.79 P2RY12 (0.57) MAOAKDM4EKMT2AMTNR1AMTNR1B
SCHEMBL3696476 0.78 MAOA (0.64) CYP1A2CYP2C9GAAMAOAKDM4E
SCHEMBL22616916 0.76 MAOA (0.62) SMN1; SMN2MAOAKDM4EKMT2AMTNR1A
SCHEMBL19308466 0.75 P2RY12 (0.71) SMN1; SMN2RAB9ANPC1KDM4EKMT2A
SCHEMBL19308451 0.75 KDM4E (0.74) CYP1A2CYP2C19MAOAKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 SMN1; SMN2 4428/4885RAB9A 1788/4885NPC1 3728/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 SMN1; SMN2 4428/4885RAB9A 1788/4885NPC1 3728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.